Talaris Therapeutics (NASDAQ:TALS) Shares Up 7.7%

Talaris Therapeutics, Inc. (NASDAQ:TALS)’s share price shot up 7.7% during trading on Thursday . The stock traded as high as $15.23 and last traded at $15.15. 844 shares changed hands during trading, a decline of 99% from the average session volume of 154,192 shares. The stock had previously closed at $14.07.

TALS has been the topic of several research reports. Morgan Stanley initiated coverage on Talaris Therapeutics in a research report on Tuesday, June 1st. They issued an “overweight” rating and a $35.00 target price on the stock. Guggenheim initiated coverage on Talaris Therapeutics in a research report on Tuesday, June 1st. They issued a “buy” rating and a $26.00 target price on the stock. Evercore ISI initiated coverage on Talaris Therapeutics in a research report on Tuesday, June 1st. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, SVB Leerink initiated coverage on Talaris Therapeutics in a research report on Tuesday, June 1st. They issued an “outperform” rating and a $21.00 target price on the stock.

The company’s 50-day moving average price is $14.83.

Talaris Therapeutics (NASDAQ:TALS) last posted its quarterly earnings data on Sunday, June 13th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($1.04). On average, equities research analysts forecast that Talaris Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

In other Talaris Therapeutics news, major shareholder Longitude Capital Partners Iii bought 235,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 11th. The shares were bought at an average price of $17.00 per share, with a total value of $3,995,000.00.

About Talaris Therapeutics (NASDAQ:TALS)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Featured Story: Does the Dogs of the Dow strategy work?

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.